113188-83-3

Usage

Uses

Used in Pharmaceutical Synthesis:
5-CHLORO-1H-INDOL-3-METHYLAMINE is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic benefits.
Used in Agrochemical Synthesis:
In the agrochemical industry, 5-CHLORO-1H-INDOL-3-METHYLAMINE is utilized as a building block in the creation of agrochemicals, potentially enhancing crop protection and yield.
Used as a Monoamine Oxidase Inhibitor:
5-CHLORO-1H-INDOL-3-METHYLAMINE is studied for its potential use as a monoamine oxidase inhibitor, which could be beneficial in the treatment of various psychiatric and neurological disorders by modulating monoamine levels in the brain.
Used as a Tryptamine Receptor Modulator:
5-CHLORO-1H-INDOL-3-METHYLAMINE is also being investigated for its potential as a tryptamine receptor modulator, which may have implications for the treatment of conditions related to the serotonin system.
Used in Cancer Treatment Research:
5-CHLORO-1H-INDOL-3-METHYLAMINE has been studied for its potential role in the treatment of cancer, with research exploring its effects on various types of cancer cells and its possible integration into cancer therapeutic strategies.
Used in Neurodegenerative Disease Treatment Research:
Additionally, 5-CHLORO-1H-INDOL-3-METHYLAMINE is being examined for its potential application in the treatment of neurodegenerative diseases, given its possible neuroprotective and restorative properties.

Upstream product

• 827-01-0 5-chloro-1H-indole-3-carboxaldehyde 
• 1261024-31-0 5-chloro-1H-indole-3-carbaldehyde oxime 

Downstream Products

• 1597411-07-8 (4aS,9aS)-4a,6-dichloro-2-phenyl-9-tosyl-4,4a,9,9a-tetrahydro-[1,3]oxazino[6,5-b]indole 
• 1597410-11-1 C₁₆H₁₃ClN₂O 

Relevant academic research and scientific papers

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

Synthesis, characterization, and SAR studies of new (1H-indol-3-yl)alkyl-3- (1H-indol-3-yl)propanamide derivatives as possible antimicrobial and antitubercular agents

In this article, we report herein the SAR studies of a series of (1H-indol-3-yl)alkyl-3-(1H-indol-3-yl)propanamide 10(a-j), 11(a-j). The synthesized compounds were evaluated for their preliminary in vitro antibacterial, antifungal activity and were screened for antitubercular activity against Mycobacterium tuberculosis H37Rv strain. The synthesized compounds displayed interesting antimicrobial activity.

NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1) wherein R1, R2, R4, R6, E, n, Y1, Y2, Y3, Y4, Y5, L, B, R8, and m are as defined in the claims.

NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1), wherein R1, R2, R4, R5, R6, E, n, Y1, Y2, Y3, Y4, Y5, B, R8, and m are as defined in the claims.

NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1) wherein R1, R2, R4, R6, E, n, Y1, Y2, Y3, Y4, Y5, L, B, R8, and m are as defined in the claims.

NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1), wherein R1, R2, R4, R5, R6, E, n, Y1, Y2, Y3, Y4, Y5, B, R8, and m are as defined in the claims.

INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.